Chongqing Zhifei Biological Products Co., Ltd.
Corporate Profile
Chongqing Zhifei Biological Products Co., Ltd. stands as a titan in the healthcare sector. With a valuation of $5.43 Billion, the company employs over 7220 people worldwide. Headquartered in Chongqing, China, it continues to drive innovation and maintain its market dominance.
Strategy, capital, and competitive context
Chongqing Zhifei Biological Products Co., Ltd. operates in healthcare with headquarters in Chongqing, China (founded 2002). The headline market cap of $5.43B reflects how public markets are pricing the equity right now; it can swing on rates, sector sentiment, and a handful of product cycles. Revenue of $1.51B is shown as a coarse annualized snapshot for orientation—always compare to the latest audited financials.
From a capital-allocation lens, we watch how reinvestment (R&D, capex, M&A) maps to returns and balance-sheet flexibility. A wide gap between revenue growth and multiple expansion often signals shifting expectations about moat durability, regulation, or geographic mix. Where we publish charts, they are built from the site's structured history fields and may be interpolated when filings are sparse—see methodology for limitations.
Competitive benchmarking on this page uses linked peers when available; treat it as a starting point for industry mapping, not a buy/sell screen. Ticker 300122 is displayed for convenience; verify exchange codes before trading.
Editorial note: this section is authored in-house to explain how we connect metrics to meaning. It is updated when material fundamentals change; report issues on corrections.
Financial History
Verified multi-year history for Chongqing Zhifei Biological Products Co., Ltd. is not yet available in our database. We publish charts only from documented data points—not synthetic estimates.
Read our methodologyIn-Depth Analysis
Data Sources & Methodology
Figures for Chongqing Zhifei Biological Products Co., Ltd. are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.